Skip to main content
Premium Trial:

Request an Annual Quote

US Genomics Secures $25M Financing

NEW YORK, May 7 - US Genomics of Woburn, Mass., announced today that it has raised $25 million in financing led by Fidelity Biosciences Group of Boston, an affiliate of financial giant Fidelity Investments.


New investors in the round include Zero Stage Capital of Cambridge, Mass., and China Development Industrial Bank of Taiwan, joining previous investors HealthCare Ventures of Princeton, NJ, and CB Health Ventures of Boston.


With the financing, the company is expanding its board of directors, which includes Craig Venter, to seven members with Mark Peterson, president of Fidelity Biosciences, and Ben Bronstein, managing director of Zero Stage Capital, taking seats on the board while Ian Chang, formerly the company's chief financial officer, leaves the firm, to pursue other interests, a US Genomics spokeswoman told GenomeWeb.


Founded in January 1998, the company previously had taken in $19.3 million in three rounds of venture capital investment.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.